Human LILRB5 / CD85c / LIR-8 Protein-蛋白质/抗原/多肽-试剂-生物在线
北京百普赛斯生物科技股份有限公司
Human LILRB5 / CD85c / LIR-8 Protein

Human LILRB5 / CD85c / LIR-8 Protein

商家询价

产品名称: Human LILRB5 / CD85c / LIR-8 Protein

英文名称: Human LILRB5 / CD85c / LIR-8 Protein

产品编号: CDC-H5220

产品价格: 0

产品产地: USA

品牌商标: ACROBiosystems

更新时间: null

使用范围: null

北京百普赛斯生物科技股份有限公司
  • 联系人 :
  • 地址 : 北京经济技术开发区宏达北路8号5号楼4层
  • 邮编 : 100176
  • 所在区域 : 北京
  • 电话 : 点击查看
  • 传真 : 点击查看
  • 邮箱 : order.cn@acrobiosystems.com

分子量:42.7 kDa

纯度:>92% as determined by SDS-PAGE.

内毒素:Less than 1.0 EU per μg of the Human Serpin E2, His Tag by the LAL method.

Buffer:20 mM NaAc, 100 mM NaCl,  PH6.5

生物活性:Measured by its ability to inhibit trypsin cleavage of a fluorogenic peptide substrate, Mca - RPKPVE - Nval - WRK(Dnp) - NH2.

产品特性:Human Serpin E2, His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 42.7 kDa. The predicted N-terminus is Ser 20. The reducing (R) protein migrates as 45-48 kDa in SDS-PAGE  due to glycosylation.

产品背景:SERPINE2 is also known as Glia-derived nexin (GDN), Peptidase inhibitor 7 (PI7), Protease nexin 1(PN1). SERPINE2 is a secreted glycoprotein which belongs to the serpin family. SerpinE1 is the primary physiological inhibitor of the two plasminogen activators urokinase (uPA) and tissue plasminogen activator (tPA). PAI-1 / GDN  is also implicated in adipose tissue development. It suggests that PAI-1 inhibitors serve in the control of atherothrombosis. Defects in Serpin E1 / PN1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency) which is characterized by abnormal bleeding due to SerpinE1 defect in the plasma. 
SDS-PAGE